266 related articles for article (PubMed ID: 21348825)
21. Targeting nitrosative stress for neurovascular protection: new implications in brain diseases.
Tao RR; Ji YL; Lu YM; Fukunaga K; Han F
Curr Drug Targets; 2012 Feb; 13(2):272-84. PubMed ID: 22023405
[TBL] [Abstract][Full Text] [Related]
22. Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.
Dunkel P; Chai CL; Sperlágh B; Huleatt PB; Mátyus P
Expert Opin Investig Drugs; 2012 Sep; 21(9):1267-308. PubMed ID: 22741814
[TBL] [Abstract][Full Text] [Related]
23. Survivin: a target from brain cancer to neurodegenerative disease.
Baratchi S; Kanwar RK; Kanwar JR
Crit Rev Biochem Mol Biol; 2010 Dec; 45(6):535-54. PubMed ID: 20925597
[TBL] [Abstract][Full Text] [Related]
24. Quercetin attenuates neuronal death against aluminum-induced neurodegeneration in the rat hippocampus.
Sharma DR; Wani WY; Sunkaria A; Kandimalla RJ; Sharma RK; Verma D; Bal A; Gill KD
Neuroscience; 2016 Jun; 324():163-76. PubMed ID: 26944603
[TBL] [Abstract][Full Text] [Related]
25. Exploring the potential of natural and synthetic neuroprotective steroids against neurodegenerative disorders: A literature review.
Bansal R; Singh R
Med Res Rev; 2018 Jul; 38(4):1126-1158. PubMed ID: 28697282
[TBL] [Abstract][Full Text] [Related]
26. Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia.
Calabrese V; Lodi R; Tonon C; D'Agata V; Sapienza M; Scapagnini G; Mangiameli A; Pennisi G; Stella AM; Butterfield DA
J Neurol Sci; 2005 Jun; 233(1-2):145-62. PubMed ID: 15896810
[TBL] [Abstract][Full Text] [Related]
27. Clinical potential of minocycline for neurodegenerative disorders.
Blum D; Chtarto A; Tenenbaum L; Brotchi J; Levivier M
Neurobiol Dis; 2004 Dec; 17(3):359-66. PubMed ID: 15571972
[TBL] [Abstract][Full Text] [Related]
28. Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases.
Waldmeier P; Bozyczko-Coyne D; Williams M; Vaught JL
Biochem Pharmacol; 2006 Nov; 72(10):1197-206. PubMed ID: 16901468
[TBL] [Abstract][Full Text] [Related]
29. The neuroprotective role of creatine.
Klein AM; Ferrante RJ
Subcell Biochem; 2007; 46():205-43. PubMed ID: 18652079
[TBL] [Abstract][Full Text] [Related]
30. Amelioration of neurodegenerative diseases by cell death-induced cytoplasmic delivery of humanin.
Park TY; Kim SH; Shin YC; Lee NH; Lee RK; Shim JH; Glimcher LH; Mook-Jung I; Cheong E; Kim WK; Honda F; Morio T; Lim JS; Lee SK
J Control Release; 2013 Mar; 166(3):307-15. PubMed ID: 23298615
[TBL] [Abstract][Full Text] [Related]
31. The role of natural products in the discovery of new drug candidates for the treatment of neurodegenerative disorders I: Parkinson's disease.
Campos HC; da Rocha MD; Viegas FP; Nicastro PC; Fossaluzza PC; Fraga CA; Barreiro EJ; Viegas C
CNS Neurol Disord Drug Targets; 2011 Mar; 10(2):239-50. PubMed ID: 20874702
[TBL] [Abstract][Full Text] [Related]
32. Current Therapeutic Molecules and Targets in Neurodegenerative Diseases Based on in silico Drug Design.
Sehgal SA; Hammad MA; Tahir RA; Akram HN; Ahmad F
Curr Neuropharmacol; 2018; 16(6):649-663. PubMed ID: 29542412
[TBL] [Abstract][Full Text] [Related]
33. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders.
Mattson MP
Neuromolecular Med; 2003; 3(2):65-94. PubMed ID: 12728191
[TBL] [Abstract][Full Text] [Related]
34. Targeting New Candidate Genes by Small Molecules Approaching Neurodegenerative Diseases.
Fan HC; Chi CS; Cheng SN; Lee HF; Tsai JD; Lin SZ; Harn HJ
Int J Mol Sci; 2015 Dec; 17(1):. PubMed ID: 26712747
[TBL] [Abstract][Full Text] [Related]
35. Hesperidin as a Neuroprotective Agent: A Review of Animal and Clinical Evidence.
Hajialyani M; Hosein Farzaei M; Echeverría J; Nabavi SM; Uriarte E; Sobarzo-Sánchez E
Molecules; 2019 Feb; 24(3):. PubMed ID: 30759833
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disorders.
Lewandowski SA; Fredriksson L; Lawrence DA; Eriksson U
Pharmacol Ther; 2016 Nov; 167():108-119. PubMed ID: 27524729
[TBL] [Abstract][Full Text] [Related]
37. Neuroprotective action of lithium in disorders of the central nervous system.
Chiu CT; Chuang DM
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Jun; 36(6):461-76. PubMed ID: 21743136
[TBL] [Abstract][Full Text] [Related]
38. The Therapeutic Potential of Celastrol in Central Nervous System Disorders: Highlights from In Vitro and In Vivo Approaches.
Schiavone S; Morgese MG; Tucci P; Trabace L
Molecules; 2021 Aug; 26(15):. PubMed ID: 34361850
[TBL] [Abstract][Full Text] [Related]
39. AMPK-mediated regulation of neuronal metabolism and function in brain diseases.
Liu YJ; Chern Y
J Neurogenet; 2015; 29(2-3):50-8. PubMed ID: 26119401
[TBL] [Abstract][Full Text] [Related]
40. Flavopiridol: an antitumor drug with potential application in the treatment of neurodegenerative diseases.
Pallàs M; Verdaguer E; Jordà EG; Jiménez A; Canudas AM; Camins A
Med Hypotheses; 2005; 64(1):120-3. PubMed ID: 15533627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
